Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7393022 | 0.79 | MAPT (0.55) | MAPTSMN1; SMN2HPGDRECQLALDH1A1 | |
| SCHEMBL2068948 | 0.76 | MAPT (0.55) | MAPTSMN1; SMN2HPGDRECQLALDH1A1 | |
| SCHEMBL9689377 | 0.73 | MAPT (0.62) | MAPTSMN1; SMN2HPGDRECQLALDH1A1 | |
| SCHEMBL7393998 | 0.72 | DRD3 (0.51) | MAPTSMN1; SMN2HPGDRECQLALDH1A1 | |
| SCHEMBL2069406 | 0.71 | NPC1 (0.49) | MAPTSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL10203080 | 0.70 | MAPT (0.58) | MAPTSMN1; SMN2HPGDRECQLALDH1A1 | |
| SCHEMBL2070164 | 0.70 | MAPT (0.58) | MAPTSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL13604237 | 0.68 | CASP3 (0.49) | MAPTSMN1; SMN2HPGDALDH1A1NPC1 | |
| SCHEMBL2071610 | 0.68 | NPC1 (0.43) | MAPTSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL27367412 | 0.68 | MAPT (1.00) | MAPTSMN1; SMN2HPGDALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906546-B2 | Tetrahydrocarbazoles and derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100216833-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | DEHMLOW HENRIETTA | 2010-08-26 | — | — | US | disclosed |
| EP-1732892-B1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | EP | disclosed |
| EP-1732892-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092856-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215577-A1 | Tetrahydrocarbazoles and derivatives | HOFFMANN-LA ROCHE INC. | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216833-A1 | TETRAHYDROCARBAZOLES AND DERIVATIVES | NR1H3, NR1H2, NR1H4 | MAPT 920/4885SMN1; SMN2 1648/4885HPGD 2120/4885 |
| US-20050215577-A1 | Tetrahydrocarbazoles and derivatives | NR1H3, NR1H2, NR1H4 | MAPT 920/4885SMN1; SMN2 1648/4885HPGD 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.